Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis
ABSTRACT: Objectives: This study aimed to evaluate the efficacy and safety of oritavancin (ORI) versus comparators for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) based on available clinical studies. Methods: PubMed, Cochrane Library and Embase were searched from d...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Journal of Global Antimicrobial Resistance |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716521001120 |
id |
doaj-40757b107c864c96a0d2fb718875420d |
---|---|
record_format |
Article |
spelling |
doaj-40757b107c864c96a0d2fb718875420d2021-06-19T04:54:17ZengElsevierJournal of Global Antimicrobial Resistance2213-71652021-06-0125380389Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysisHuan Zhang0Weiying Zhou1Jin Wang2Yun Cai3Centre of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing 100853, China; College of Pharmacy, Chongqing Medical University, Chongqing 400016, ChinaCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, ChinaCentre of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing 100853, ChinaCentre of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing 100853, China; Corresponding author. Mailing address: 28 Fu Xing Road, Beijing 100853, People's Republic of China. Tel.: +86 10 6693 7166; Fax: +86 10 8821 4425.ABSTRACT: Objectives: This study aimed to evaluate the efficacy and safety of oritavancin (ORI) versus comparators for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) based on available clinical studies. Methods: PubMed, Cochrane Library and Embase were searched from database inception to 28 July 2020 to identify clinical studies assessing the efficacy and safety of ORI and comparator antibiotics for the treatment of ABSSSIs. Primary efficacy outcome, investigator-assessed clinical cure, lesion size reduction ≥20%, additional post-treatment antibiotics, and 30-day emergency room (ER) visits and readmission were assessed as efficacy outcomes. Adverse events (AEs) and mortality were assessed as safety outcomes. I2 statistic was calculated for heterogeneity, and a fixed-effects or random-effects model was used for estimation of the risk ratio (RR). Results: A total of 9213 patients from two randomised clinical trials (RCTs) and four cohort studies were included in this meta-analysis. ORI was statistically non-inferior to control agents in all efficacy and safety outcomes. Moreover, ORI significantly reduced the occurrence of 30-day readmission (RR = 0.42; P = 0.0004) and drug-related AEs (RR = 0.78; P = 0.002). In the subgroup analysis, ORI also had a lower rate of 30-day ER visits in the outpatient setting (RR = 0.34; P < 0.00001). Conclusion: ORI was not inferior to comparators for the treatment of ABSSSIs. Meanwhile, it showed advantages in reducing the rate of readmission and drug-related AEs. More high-quality and large-scale RCTs are required to further confirm the efficacy and safety of ORI. [Trial registration: PROSPERO ID: CRD42020201942]http://www.sciencedirect.com/science/article/pii/S2213716521001120OritavancinAcute bacterial skin and skin-structure infectionABSSSIEfficacySafetyMeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Huan Zhang Weiying Zhou Jin Wang Yun Cai |
spellingShingle |
Huan Zhang Weiying Zhou Jin Wang Yun Cai Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis Journal of Global Antimicrobial Resistance Oritavancin Acute bacterial skin and skin-structure infection ABSSSI Efficacy Safety Meta-analysis |
author_facet |
Huan Zhang Weiying Zhou Jin Wang Yun Cai |
author_sort |
Huan Zhang |
title |
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
title_short |
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
title_full |
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
title_fullStr |
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
title_full_unstemmed |
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
title_sort |
efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis |
publisher |
Elsevier |
series |
Journal of Global Antimicrobial Resistance |
issn |
2213-7165 |
publishDate |
2021-06-01 |
description |
ABSTRACT: Objectives: This study aimed to evaluate the efficacy and safety of oritavancin (ORI) versus comparators for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) based on available clinical studies. Methods: PubMed, Cochrane Library and Embase were searched from database inception to 28 July 2020 to identify clinical studies assessing the efficacy and safety of ORI and comparator antibiotics for the treatment of ABSSSIs. Primary efficacy outcome, investigator-assessed clinical cure, lesion size reduction ≥20%, additional post-treatment antibiotics, and 30-day emergency room (ER) visits and readmission were assessed as efficacy outcomes. Adverse events (AEs) and mortality were assessed as safety outcomes. I2 statistic was calculated for heterogeneity, and a fixed-effects or random-effects model was used for estimation of the risk ratio (RR). Results: A total of 9213 patients from two randomised clinical trials (RCTs) and four cohort studies were included in this meta-analysis. ORI was statistically non-inferior to control agents in all efficacy and safety outcomes. Moreover, ORI significantly reduced the occurrence of 30-day readmission (RR = 0.42; P = 0.0004) and drug-related AEs (RR = 0.78; P = 0.002). In the subgroup analysis, ORI also had a lower rate of 30-day ER visits in the outpatient setting (RR = 0.34; P < 0.00001). Conclusion: ORI was not inferior to comparators for the treatment of ABSSSIs. Meanwhile, it showed advantages in reducing the rate of readmission and drug-related AEs. More high-quality and large-scale RCTs are required to further confirm the efficacy and safety of ORI. [Trial registration: PROSPERO ID: CRD42020201942] |
topic |
Oritavancin Acute bacterial skin and skin-structure infection ABSSSI Efficacy Safety Meta-analysis |
url |
http://www.sciencedirect.com/science/article/pii/S2213716521001120 |
work_keys_str_mv |
AT huanzhang efficacyandsafetyoforitavancinforthetreatmentofacutebacterialskinandskinstructureinfectionsasystematicreviewandmetaanalysis AT weiyingzhou efficacyandsafetyoforitavancinforthetreatmentofacutebacterialskinandskinstructureinfectionsasystematicreviewandmetaanalysis AT jinwang efficacyandsafetyoforitavancinforthetreatmentofacutebacterialskinandskinstructureinfectionsasystematicreviewandmetaanalysis AT yuncai efficacyandsafetyoforitavancinforthetreatmentofacutebacterialskinandskinstructureinfectionsasystematicreviewandmetaanalysis |
_version_ |
1721371849016737792 |